Supernus Pharmaceuticals Inc.

06/17/2025 | Press release | Distributed by Public on 06/17/2025 14:41

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 16, 2025 Supernus Pharmaceuticals, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"). The definitive proxy statement pertaining to the Annual Meeting was previously filed by the Company with the Securities and Exchange Commission on April 30, 2025. As of the close of business on April 22, 2025, there were 55,989,623 shares of common stock outstanding and entitled to vote. The tabulation of votes for each proposal voted on by the stockholders was as follows:
Proposal 1: Election of Class I Directors, each to serve until the Annual Meeting of the Company in 2028.
Name Votes For Votes Withheld Broker Non-Votes
Carolee Barlow, M.D., Ph.D 46,104,993 1,426,932 2,024,865
Jack A. Khattar 46,511,003 1,020,922 2,024,865
Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers.
Votes For Votes Against Abstain Broker Non-Votes
45,796,936 1,701,777 33,212 2,024,865
Proposal 3: Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2025.
Votes For Votes Against Abstain Broker Non-Votes
49,230,498 310,868 15,424 0
Supernus Pharmaceuticals Inc. published this content on June 17, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 17, 2025 at 20:41 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io